title: Intrathecal ACNU treatment of B16 melanoma leptomeningeal metastasis in a new athymic rat model.
abstract: To evaluate new cytotoxic drugs for intrathecal treatment we developed an experimental model of leptomeningeal metastasis by intracisternal injection of 10(4) B16-F10 melanoma cells in nude rats. One hour in vitro incubation with 20 micrograms/ml ACNU (area under the drug concentration-time curve = 1200 microgramsxmin/ml) induced a 4-log kill of B16 melanoma cells. A single or repeated non-toxic dose of 1 mg/kg was injected into the cisterna magna of rats inoculated with tumor (area under the drug concentration-time curve assuming an even cerebrospinal fluid distribution greater than 7000 microgramsxmin/ml). Median survival free of symptoms was 16 days (range 14-27) for controls (n = 9) and 18 days (range 17-23) for rats treated with ACNU on day 4 (n = 9). Animals treated both on day 2 and 8 (n = 8) developed symptoms on day 21 (range 13-35). Neurological symptoms and neuropathological examination in animals with increased survival indicated local suppression of tumor growth in the cisterna magna but increased spinal seeding and mass growth. From these results and the available pharmacokinetic data on ACNU it is concluded that bolus injection of ACNU--although locally effective--is not a sufficient treatment of widespread leptomeningeal metastasis. An increased therapeutic efficacy might be achieved by ventriculolumbar perfusion.
authors.affiliation: Department of Neurology, University of Tübingen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Schabet
authors.forename: P
authors.initials: P
authors.lastname: Ohneseit
authors.forename: R
authors.initials: R
authors.lastname: Buchholz
authors.forename: L
authors.initials: L
authors.lastname: Santo-Höltje
authors.forename: H
authors.initials: H
authors.lastname: Schmidberger
mesh_terms: D000818:Animals; D002946:Cisterna Magna; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006849:Hydrocephalus / Q000209:etiology; D007278:Injections, Spinal; D008546:Melanoma, Experimental / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D008577:Meningeal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D015376:Nimustine / Q000008:administration & dosage / Q000627:therapeutic use*; D010291:Paresis / Q000209:etiology; D051381:Rats; D011923:Rats, Nude; D013116:Spinal Cord / Q000473:pathology
chemical_list: D015376:Nimustine